trial · primary record
NX-5948
B-cell Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 150 |
| Primary completion | 2033-05 |
| Primary endpoint | Number of participants with treatment-emergent adverse events |
| Registry ID | NCT07520006 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:12.553Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07520006
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Nx-5948 · compound